CK Li, GCF Chan, KW Chik, SY Ha, YL Lau, ACW Lee, CY Lee, CK Li, SC Ling, CW Luk, MMK Shing, HL Yuen, PMP Yuen

Abstract

The Hong Kong Paediatric Haematology and Oncology Study Group conducted clinical studies on treatment of various paediatric cancers in Hong Kong. This article reported the treatment result of the various cancers presented in the annual workshop in February 2000. The five-year overall survival and event free survival were 80.2% and 62% for Acute Lymphoblastic Leukaemia, and were 60% and 53% for Acute Myeloid Leukaemia respectively. The other cancers with shorter follow up had three years overall and event free survival as follow: 75% and 62% for Medulloblastoma, 74% and 67% for Non-Hodgkin Lymphoma, 100% and 91% for extracranial Germ Cell Tumour, 30% and 20% for advanced neuroblastoma, 68% and 52% for Ewing's Sarcoma, 87% and 79% for Wilms' Tumour, 82% and 80% for Osteosarcoma, 56% and 45% for Rhabdomyosarcoma, and 60% and 50% for Hepatoblastoma respectively. The protocols had a high rate of adoption by the various hospitals, over 95% eligible patients were treated according to protocols. The toxicity of these protocols was acceptable with treatment related mortality less than 5% in most protocols.

香港兒科血液及腫瘤研究小組組織了關於香港兒童各種癌症治療的臨床研究。這篇文章在 2000 年 2 月的年度報告會上報導了各種癌症的治療結果。急性淋巴細胞性白血病的 5 年總存活率及無並發症存活率分別為 80.2%及 62%，而急性髓細胞性白血病則分別為 60% 及 53%。其他癌症經三年的短期隨訪，總存活率及無併發症存活率分別是：成神經管細胞瘤為 75% 及 62%；非何傑金氏淋巴瘤為 74% 及 67%；顱外的胚細胞瘤為 100% 及 91%；已播散成神經細胞瘤為 30% 及 20%；尤因氏肉瘤為 68% 及 52%；威爾姆斯氏瘤為 87% 及 79%；骨肉瘤為 82% 及80%；橫紋肌肉瘤為 56% 及 45%；肝母細胞瘤為 60% 及 50%。不同的醫院都採用極為相似的治療方案，超過 95% 的被選病人均按照此方案治療。在多數治療方案中低於 5% 的死亡率與治療方案中藥物的毒性有關。